357 related articles for article (PubMed ID: 25792524)
1. Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
Ostrand-Rosenberg S; Horn LA; Alvarez JA
Cancer Immunol Immunother; 2015 Oct; 64(10):1287-93. PubMed ID: 25792524
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
[TBL] [Abstract][Full Text] [Related]
3. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
4. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.
Haile ST; Horn LA; Ostrand-Rosenberg S
Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296
[TBL] [Abstract][Full Text] [Related]
5. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
6. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
7. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.
Sugita S; Usui Y; Horie S; Futagami Y; Aburatani H; Okazaki T; Honjo T; Takeuchi M; Mochizuki M
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2862-70. PubMed ID: 19182257
[TBL] [Abstract][Full Text] [Related]
8. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
9. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
[TBL] [Abstract][Full Text] [Related]
10. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.
Raptopoulou AP; Bertsias G; Makrygiannakis D; Verginis P; Kritikos I; Tzardi M; Klareskog L; Catrina AI; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2010 Jul; 62(7):1870-80. PubMed ID: 20506224
[TBL] [Abstract][Full Text] [Related]
11. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.
Deng R; Cassady K; Li X; Yao S; Zhang M; Racine J; Lin J; Chen L; Zeng D
J Immunol; 2015 Jan; 194(2):560-74. PubMed ID: 25488990
[TBL] [Abstract][Full Text] [Related]
12. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
[TBL] [Abstract][Full Text] [Related]
14. EpCAM-specific vaccine response by modified antigen and chimeric costimulatory molecule in cynomolgus monkeys.
Neighbors M; Apt D; Chang JC; Brinkman A; Sipos-Solman I; Ong R; Leong S; Punnonen J
J Immunother; 2008 Sep; 31(7):644-55. PubMed ID: 18600180
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
16. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
[TBL] [Abstract][Full Text] [Related]
17. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.
Gotsman I; Grabie N; Dacosta R; Sukhova G; Sharpe A; Lichtman AH
J Clin Invest; 2007 Oct; 117(10):2974-82. PubMed ID: 17853943
[TBL] [Abstract][Full Text] [Related]
18. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
19. Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.
Terawaki S; Tanaka Y; Nagakura T; Hayashi T; Shibayama S; Muroi K; Okazaki T; Mikami B; Garboczi DN; Honjo T; Minato N
Int Immunol; 2007 Jul; 19(7):881-90. PubMed ID: 17606978
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules.
Chapoval AI; Zhu G; Chen L
Mol Biotechnol; 2002 Jul; 21(3):259-64. PubMed ID: 12102550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
